Continuous glucose monitoring devices have transformed outpatient diabetes management over the past decade, and that same sensor technology is increasingly moving into inpatient settings, where regulatory clearance for hospital use has expanded and evidence supporting inpatient CGM for glycemic management has grown considerably. This shift carries real supply chain implications distinct from outpatient CGM distribution.
How Inpatient Use Differs From Outpatient
- Sensors need to be stocked and available for patients arriving without their own device, or for initiating monitoring on patients who weren't previously on CGM, requiring facility-held inventory rather than relying entirely on patient-supplied devices
- Infection control and single-use protocols differ from the outpatient context, where a patient typically wears one sensor for its full duration without facility involvement
- Integration with inpatient glucose management protocols and nursing workflows requires coordination that outpatient CGM distribution never had to address
The Clinical Case Driving Adoption
Traditional inpatient glucose monitoring relies on periodic fingerstick checks, which miss the trend data and rapid fluctuations that continuous monitoring captures — a meaningful gap for patients with unstable glycemic control, where a fingerstick every few hours can miss a dangerous excursion that CGM would have flagged in real time.
Supply Chain Considerations for Facilities Adopting This
Facilities building inpatient CGM programs need to establish new stocking protocols, likely through pharmacy or a dedicated diabetes management supply line rather than general nursing supply, and should expect device and sensor costs to be a genuinely new budget line rather than a substitution for existing fingerstick supply costs, since most programs run both in parallel initially.
Facilities building diabetes management supply programs can review Healix Medical Supply's diagnostic equipment catalog.
